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Summary
Inactivation of the von Hippel-Lindau (VHL) gene is associated with the development of highly vascularized tumors. pVHL
targets the  subunits of hypoxia inducible factor (HIF) for ubiquitin-mediated degradation in an oxygen-dependent manner.
Although pVHL-deficient tumor cell lines demonstrate constitutive stabilization and activation of HIF, it has yet to be shown
that loss of murine Vhl alone is sufficient to dysregulate HIF. We utilized a genetic approach to demonstrate that loss of
Vhl is sufficient not only to stabilize HIF- subunits under normoxia, but also fully activate HIF-mediated responses. These
studies have implications for the hierarchy of signaling events leading to HIF stabilization, nuclear translocation, and target
gene expression. We further demonstrate that loss of murine Vhl does not promote teratocarcinoma growth, indicating
that other genetic changes must occur to facilitate Vhl-mediated tumorigenesis.
Introduction its  domain with elongins B/C and Cul2 to form the VBC com-
plex, an E3 ubiquitin ligase. This multiprotein complex targets
proteins for ubiquitin-mediated degradation, analogous to thevon Hippel-Lindau disease is an autosomal dominant hereditary
cancer syndrome. Patients heterozygous for one inactivating S. cerevisiae SCF (Skp1/Cdc53/F-box) ubiquitination machinery
(Pause et al., 1997; Lonergan et al., 1998; Lisztwan et al., 1999).mutation within the von Hippel-Lindau (VHL) gene are predis-
posed to the development of pheochromocytomas and a variety Although pVHL has no sequence homology to any known pro-
teins, it is functionally similar to the F box protein of SCF byof highly vascularized tumors, including renal clear cell carcino-
mas, retinal angiomas, and hemangioblastomas (Maher and binding specific substrates through its  domain (Ohh et al.,
2000).Kaelin,, 1997). Within these tumors, the second VHL allele has
been rendered inactive by deletions, mutations, or hypermethyl- Major targets of the VBC complex include the regulatory
 subunits of the heterodimeric transcription factor hypoxiaation. VHL is therefore a classic tumor suppressor conforming to
the Knudson two hit hypothesis in which the second inactivating inducible factor (HIF). HIF modulates both cellular and systemic
responses to changes in oxygen (O2) concentrations by stimulat-mutation occurs within somatic cells. A majority of sporadic
renal clear cell carcinomas also exhibit biallelic loss of VHL ing the expression of genes involved in energy metabolism,
angiogenesis, hematopoiesis, and O2 delivery. Proteasome in-function, further supporting VHL’s role as a tumor suppressor
(Foster et al., 1994; Gnarra et al., 1994). Animal models demon- hibitor studies show that at high levels of O2 (21%), the VBC
complex binds HIF- subunits (HIF-1 and HIF-2), targetingstrate that deletion of murine Vhl function results in lethality, as
Vhl/ mice die in utero between E10.5–E12 due to placental them for ubiquitination and degradation via the 26S proteasome
(Maxwell et al., 1999). Low O2 (hypoxia) disrupts the associationvascular abnormalities (Gnarra et al., 1997). Hepatocyte-specific
loss of Vhl in adult mice results in the formation of hemangiomas of pVHL with HIF- subunits, which then dimerize with constitu-
tively expressed ARNT/HIF- to form transcriptionally activewithin the liver, a phenotype rarely observed in human VHL
patients (Haase et al., 2001). HIF. Mutations within the  domain of pVHL disrupt its interac-
tion with HIF- subunits leading to constitutive HIF- stabiliza-pVHL, the protein product of the VHL gene, interacts through
S I G N I F I C A N C E
Loss of the pVHL tumor suppressor protein is associated with tumors within the CNS, retina, and kidney. pVHL targets the  subunits
of hypoxia inducible factor (HIF) for ubiquitin-mediated degradation in an O2-regulated manner. The degree to which constitutive
HIF stabilization contributes to VHL disease has been studied in tumor-derived cell lines that contain other genetic lesions. We
generated primary Vhl/ ES cells that display maximal HIF activity under normoxic conditions. These results contrast published reports
indicating that full HIF activity requires multiple pVHL-independent, O2-regulated steps, including nuclear transport and transactivation.
Surprisingly, Vhl/ ES cells generate smaller teratocarcinomas than controls, suggesting a growth disadvantage in pVHL-deficient
primary cells. Therefore, VHL’s tumor suppressor activity may be manifested only in a background of other mutations.
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tion and HIF activity (Cockman et al., 2000; Ohh et al., 2000). a multistep process responsive to O2 levels, it is unclear to what
degree these events can occur in normoxic conditions. Here,Furthermore, VHL/ renal clear cell carcinoma (RCC) cell lines
fail to degrade HIF- subunits under normoxic conditions. These we utilize gene targeting of Vhl in mouse embryonic stem (ES)
cells to demonstrate that loss of Vhl is sufficient to dysregulatecells display constitutive expression of HIF targets including
genes encoding erythropoietin (EPO), vascular endothelial HIF degradation, nuclear accumulation, DNA binding activity,
and downstream target gene activation, conferring a hypoxicgrowth factor (VEGF), glucose transporter (GLUT-1), and phos-
phoglycerate kinase (PGK) (Iliopoulos et al., 1996; Maxwell et phenotype to normoxic Vhl/ ES cells. Unexpectedly, Vhl/
teratocarcinomas are smaller by volume and mass comparedal., 1999; Krieg et al., 2000). In addition to its role as part of
an E3 ubiquitin ligase, pVHL is required for proper fibronectin to Vhl/ tumors, suggesting that stimulation of the HIF pathway
is not sufficient to induce tumor growth and additional geneticdeposition, cytoskeletal reorganization, growth arrest upon se-
rum withdrawal, and contact inhibition, although the underlying changes must occur to facilitate tumorigenesis in the absence
of Vhl.mechanisms for these properties remain unclear (Ohh et al.,
1998; Pause et al., 1998; Hoffman et al., 2001; Kamada et al.,
2001; Bindra et al., 2002). Defects within all of these pathways Results
can be reversed by reintroduction of wild-type pVHL into VHL/
RCC cells. Generation of Vhl/ ES cells
Although renal cancer cell lines deficient for pVHL exhibit consti-The interaction of pVHL with HIF- is one of several O2-
dependent events thought to regulate HIF activity. First, pVHL tutive expression of HIF target genes under normoxic condi-
tions, loss of VHL alone has not been shown to result in completebinding to HIF- subunits is dependent upon hydroxylation of
key proline residues within the O2-dependent degradation (ODD) disruption of HIF regulation and promotion of tumor formation.
To examine the precise role of Vhl in these processes, we utilizeddomain of HIF- (Ivan et al., 2001; Jaakkola et al., 2001). A
recently defined family of HIF prolyl-hydroxylases (HIF-PHs) cat- a genetic strategy based on Vhl/ mouse J1 embryonic stem
(ES) cells (Gnarra et al., 1997). The recombined locus maintainsalyzes this iron- and O2-dependent reaction. All three elements
of this pathway are conserved in C. elegans, Drosophila, and intact the Vhl promoter region, the first 23 codons, and 3 un-
translated region (Figure 1A). Homozygous Vhl/ clones weremammals (Bruick and McKnight 2001; Epstein et al., 2001).
Second, hypoxia is also believed to induce the nuclear accumu- generated from Vhl/ ES cells by selecting for loss of the re-
maining wild-type allele with increasing concentrations of G418lation of stabilized HIF- subunits, protecting them from pVHL-
mediated degradation (Kallio et al., 1999; Tanimoto et al., 2000). (Mortensen et al., 1992). Approximately 200 clones were
screened for loss of heterozygosity by Southern blot and/orThird, hypoxia-mediated HIF transactivation of target genes re-
quires interactions with coactivators p300 and CBP (Arany et PCR assays (Figures 1B and 1C). Three independently derived
Vhl/ clones were identified, none of which expressed detect-al., 1996; Jiang et al., 1997; Pugh et al., 1997; Ebert and Bunn,
1998; Carrero et al., 2000). Recent studies suggest that hydrox- able amounts of pVHL when compared to Vhl/ and Vhl/
ES cells (Figure 1D), and these were further assayed for HIFylation of a C-terminal activation domain (CAD) asparagine resi-
due by an iron- and O2-dependent asparagyl hydroxylase dis- function.
rupts HIF- binding to coactivators p300 and CBP, thereby
preventing transactivation during normoxia (Lando et al., 2002). HIF is constitutively stabilized and maintains DNA
binding activity in the absence of VhlFurthermore, hydroxylation within the CAD is thought to occur
in a pVHL-independent manner (Sang et al., 2002). Therefore, We first investigated the stabilization of HIF- proteins by West-
ern blot and electrophoretic mobility shift assay (EMSA). Immu-under normal O2 concentrations, hydroxylation of HIF- on pro-
line and asparagine residues regulates HIF’s transcriptional ac- noblots of nuclear extracts demonstrated that at 21% O2 (nor-
moxia) (Figure 2A), Vhl/ and Vhl/ ES cells express low levelstivity by targeting the protein for proteolysis and inhibiting bind-
ing to coactivators, respectively. of HIF-1 and HIF-2, which increased dramatically at 1.5%
O2 (hypoxia). In contrast, Vhl/ cells accumulated high levelsThus far, most studies correlating loss of VHL function with
HIF dysregulation have been conducted in renal tumors and of HIF-1 and HIF-2 under normoxia. Moreover, HIF-1 and
HIF-2 protein levels remained largely unchanged within nor-fully transformed cell lines. As cancer development requires
multiple genetic lesions, these cells undoubtedly contain a moxic and hypoxic extracts when normalized to the Rad50
loading control. The constitutive stabilization of HIF- subunitshighly abnormal genetic background. Although recent results
have shown that VHL inactivation is correlated with stimulation in Vhl/ cells is consistent with data reported for RCC lines
(Maxwell et al., 1999; Krieg et al., 2000).of the HIF pathway in early kidney lesions (Mandriota et al.,
2002), other genetic abnormalities were not examined. Indeed, The nuclear translocation of HIF- subunits has been re-
ported to be an O2-regulated step, independent of pVHL functioncytogenetic analysis of renal clear cell carcinomas shows that
a majority of these tumors have lost the short arm of chromo- (Tanimoto et al., 2000). To detect the localization of constitu-
tively stabilized HIF-1 in Vhl/ cells, Western blots were per-some 3 and contain a myriad of structural aberrations and unbal-
anced translocations (Gunawan et al., 2001). Although reintro- formed using cytoplasmic and nuclear fractions of extracted
proteins (Figure 2B). In Vhl/ and Vhl/ cells, stabilized HIF-1duction of VHL into RCC lines eliminates their tumorigenic
phenotype (Gnarra et al., 1996; Iliopoulos et al., 1996), this was exclusively detected in the nuclear fraction of hypoxic ex-
tracts (Figure 2B). All Vhl/ clones exhibited exclusively nuclearoccurs within a background of uncharacterized mutations, mak-
ing it difficult to identify the effects of VHL loss alone. Until now, accumulation of HIF-1 under normoxia and hypoxia. Introduc-
tion of hemagglutin-tagged (HA)-VHL into clone Vhl/.1 restoreda formal genetic study to assess the tumorigenic effects of VHL
loss in euploid primary cells has not been performed. Further- the hypoxic regulation of HIF-1, consistent with previously
reported data (Maxwell et al., 1999; Krieg et al., 2000). Thismore, although the regulation of HIF activity is believed to be
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Figure 1. Generation of Vhl/ ES cells
A: Filled boxes represent the three Vhl exons while the open box depicts the pgk-neo selectable marker within the targeting vector. The 3 flanking probe
used in Southern blots is indicated.
B: Detection of wild-type and targeted alleles in ES cells by HindIII digestion and hybridization to the 3 flanking probe revealed an 8 kb wild-type fragment
and a 4 kb mutant fragment in Vhl/ and ES clones 1, 2, and 3.
C: PCR genotyping of ES clones demonstrated a 300 bp wild-type and a 500 bp mutant product. The lower band visible within lanes 3–6 is a background
signal thought not to represent the wild-type allele because of its greater size and decreased intensity.
D: Immunoblot for pVHL in ES clones detected a 30 kDa protein in wild-type and Vhl/ ES cell whole-cell extracts but not in clones 1, 2, and 3. A pVHL-
deficient RCC cell line stably transfected with HA-tagged murine pVHL was used as a control.
“rescued” Vhl/ clone expressed levels of pVHL comparable upon the presence of functional pVHL regardless of O2 concen-
tration.to RCC lines rescued with HA-VHL (data not shown) (Iliopoulos
et al., 1996).
HIF DNA binding activity in normoxic and hypoxic Vhl/ ES Loss of Vhl is sufficient to activate HIF-mediated
cells was assessed by EMSA. Vhl/ ES cells exhibited hypoxic transcription under normoxia
induction of a DNA complex confirmed to be HIF by “supershift- To assess the transcriptional activity of HIF in Vhl/ ES cells,
ing” with an -ARNT antibody (Figure 2C, lanes 2 and 3). In reporter assays using hypoxia response element (HRE)-driven
contrast, high levels of HIF were detected in normoxic Vhl/ luciferase constructs were performed (Figure 3A). Normoxic
ES cells (Figure 2C, lanes 4, 7, and 10), which was also super- Vhl/ and Vhl/ ES cells demonstrated low levels of HIF tran-
shifted by with the ARNT antibody (Figure 2C, lanes 6, 9, and scriptional activity induced more than 10-fold by hypoxia. In
12). We conclude from these results that HIF- stabilization, contrast, although the levels of HIF activity varied between Vhl/
clones within these assays, the trend consistently showed highsubcellular localization, and DNA binding activity are dependent
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levels of HIF activity under normoxic conditions, which were
only slightly elevated by hypoxia. Use of a mutant HRE con-
struct, which contains three base pair substitutions to disrupt
HIF binding, ablated the hypoxic induction of transcriptional
activity in all cell lines demonstrating its HIF dependence. Fur-
thermore, Hif-1/ ES cells exhibited reduced levels of lucifer-
ase activity in both normoxic and hypoxic conditions, compara-
ble to levels detected using the mutant HRE construct.
Importantly, cotransfection of a plasmid encoding HA-VHL with
HRE-reporter constructs repressed normoxic HIF activity and
restored hypoxic induction of HRE-dependent transcription in
Vhl/ cells (Figure 3B).
To further investigate the function of stabilized HIF in Vhl/
cells, the activation of endogenous HIF target genes was exam-
ined. mRNA expression analysis of several known hypoxia-
responsive genes (Glut-1, Vegf, Pgk, Alda, and Bnip3) revealed
low levels of expression in normoxic Vhl/ and Vhl/ ES cells,
which were markedly induced by hypoxia (Figure 4A). In direct
contrast, the expression of HIF target genes in multiple normoxic
Vhl/ ES clones was comparable to, if not greater than, their
expression in hypoxic Vhl/ and Vhl/ ES cells. Consistent
with reporter gene data, HIF target gene expression remained
high and was not greatly affected by hypoxia in two Vhl/ ES
clones. Clone Vhl/.3 exhibited high levels of HIF target gene
expression under normoxia that was moderately induced by
hypoxia, albeit to a lesser degree than wild-type controls. This
could be simply a result of clonal variation, as extensive geno-
typing indicated the absence of contaminating Vhl/ cells in
this clone. In all other assays that analyzed HIF target gene
activation, Vhl/.3 behaved similarly to the other clones. The
expression of all target genes was primarily regulated by HIF,
as shown by their greatly reduced expression in Hif-1/ ES
cells. However, Glut-1 and Vegf transcripts can be stabilized
by hypoxia independently of HIF (Ikeda et al., 1995; Levy et al.,
1996a, 1996b), which may account for the residual hypoxic
induction of these genes in Hif-1/ ES cells.
To further assess the activation of HIF targets, VEGF secre-
tion was measured by ELISA (Figure 4B). Although the absolute
amounts of VEGF secretion varied between all clones, the pat-
tern of Vegf regulation observed by Northern blot was recapitu-
lated. VEGF secretion by Vhl/ and Vhl/ cells was substan-
tially induced by hypoxia, while secretion by Vhl/ cells under
the same conditions remained similar to their normoxic levels.
The induction of VEGF secretion by hypoxia could be restored
by reintroduction of HA-VHL into clone Vhl/.1.Figure 2. HIF stabilization and DNA binding activity in the absence of Vhl
When O2 is limiting, cells switch from oxidative phosphoryla-A: Nuclear extracts were prepared from ES cells cultured under normoxia
(21% O2) or hypoxia (1.5% O2) for 4 hr. Low levels of HIF-1and HIF-2 proteins tion to glycolysis as the primary generator of ATP (Pasteur ef-
were present under normoxia and become markedly induced by hypoxia fect). Since the constitutive stabilization of HIF in Vhl/ cells
in Vhl/ and Vhl/ ES cells. In the absence of Vhl, HIF- proteins became mimicked a hypoxic state, the glycolytic rate of and lactic acid
stabilized under normoxia at higher levels than Vhl/ and Vhl/ ES cells
production by these cells was measured. Consistent with theirand were not substantially induced by hypoxia. Nuclear protein Rad50 was
upregulation of glycolytic genes (Glut-1, Pgk, and Alda), Vhl/utilized as a loading control.
B: Immunoblot for HIF-1 in cytoplasmic and nuclear fraction revealed that cells consumed more glucose than Vhl/ and Vhl/ cells over
stabilized HIF-1 accumulated exclusively in the nucleus of Vhl/ ES cells. the course of a 1 hr normoxic incubation (Figure 4C). The higher
HIF-1 regulation was restored by stable transfection of HA-VHL into clone
glycolytic rate of Vhl/ ES cells resulted in a substantially in-Vhl/.1. Loading control -tubulin, although more abundant in cytoplasmic
creased rate of lactate production over the course of 24 hr, whenfractions, demonstrated equivalent protein amounts were loaded per cell
sample. compared to Vhl/ and Vhl/ cells (Figure 4D). The increased
C: EMSA of 5.0 g nuclear extracts prepared from cells grown under nor- glycolytic rate in and lactate production by Vhl/ .1 were sup-
moxic or hypoxic conditions for 4 hr where indicated. HIF DNA binding pressed by reintroduction of HA-VHL, demonstrating that theseactivity was maintained in Vhl/ cells under normoxia. The arrow represents
effects on glycolysis are pVHL dependent. Therefore, by thethe HIF/ARNT complex, which was shown to be specific by supershifting
with an -ARNT antibody, marked by an asterisk. criteria of stabilization, nuclear localization, DNA binding activ-
ity, target gene activation, and cellular metabolism, loss of Vhl
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Figure 3. HIF transcriptional activity is dysregulated in Vhl/ ES cells
A: ES cells were transiently transfected with wild-type (wHRE) or mutant (mHRE) reporter constructs, and transcriptional activity was measured in normoxic
(21% O2) or hypoxic (1.5% O2) cells at 16 hr. Luciferase activity detected in normoxic Vhl/ clones was not further induced by hypoxia. Data represent one
of three independent assays in which similar results were produced.
B: ES cells were cotransfected with wHRE or mHRE plus or minus a plasmid encoding HA-VHL. The presence of HA-VHL decreased the normoxic levels of
HIF activity and restored hypoxic induction. Assays were performed in triplicate and bars represent standard error.
alone is sufficient to constitutively activate HIF to hypoxic levels, cells (Figure 4B). Surprisingly, Vhl/ tumors were considerably
smaller than Vhl/ tumors after 21 or 28 days. Table 1 showsindependent of O2 signaling.
the results of four separate experiments in which Vhl/ tumors
were on average 42%–68% smaller than Vhl/ tumors. Vhl/.1Loss of Vhl does not promote tumor growth
To investigate whether loss of Vhl can enhance the tumorigenic tumors grew more slowly than Vhl/ controls as measured by
tumor volume, contrary to the findings of pVHL-deficient RCC-potential of ES cells, subcutaneous tumors were generated by
injecting Vhl/ and Vhl/ ES cells into the dorsal region of NIH- derived tumors (Figure 5B) (Iliopoulos et al., 1995). Figure 5C
shows pooled data from three separate teratocarcinoma experi-III immunodeficient mice. Clones Vhl/.1 and Vhl/.2 were used
because of their high levels of VEGF secretion relative to Vhl/ ments at 21 days, in which the masses of tumors formed by
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Figure 4. Induction of HIF target genes in normoxic Vhl/ ES cells
A: Total RNA isolated from Vhl/, Vhl/, Vhl/ clones and Hif-1/ ES cells was probed for Vegf, Glut-1, Pgk, Alda, Bnip-3, and -actin, which served as a
loading control. Expression of HIF target genes was abundant under normoxia and failed to be further induced by hypoxia in Vhl/ ES clones.
B: In vitro secretion of VEGF was measured by ELISA. VEGF secretion was greatly induced by hypoxia in Vhl/ and Vhl/ ES cells but not in Vhl/ clones.
The high level of VEGF secretion by Vhl/.1 was suppressed by reintroduction of HA-VHL.
C: A representative measurement of the glycolytic rate assessed as the rate of conversion of 3H-Glucose to 3H2O (Liang et al., 1997). Vhl/ ES cells consumed
glucose at a higher rate than controls, and this phenotype was suppressed by reintroduction of HA-VHL.
D: Change in lactate secretion measured over the course of 24 hr is depicted. Vhl/ ES cells secreted greater amounts of lactate than controls; this
phenotype was also suppressed by reintroduction of HA-VHL. All assays were performed in triplicate and bars represent standard error.
clones Vhl/.1 and Vhl/.2 were combined for an N value of 20. were present in Vhl/ tumors; however, more differentiated tis-
sue types such as skeletal muscle, cartilage, neuronal axons,The difference between the masses of Vhl/ and Vhl/ tumors
was statistically significant (p 0.003 by Student’s t test). Most adipocytes, and secretory glands were absent or extremely rare,
compared to Vhl/ tumors (data not shown). The presence ofimportantly, the growth of genetically rescued Vhl/.1  HA-
VHL tumors was similar to Vhl/ controls, demonstrating that a subset of these tissues was restored in Vhl/.1  HA-VHL
tumors (data not shown). The ability of Vhl/ ES cells to depositthis deficiency is functionally dependent upon Vhl (Figure 5C).
fibronectin in the extracellular matrix was assessed by immuno-
histochemistry. Vhl/ tumors exhibited abundant fibronectinMicrovessel density is increased in Vhl/ tumors
Gross morphological analysis revealed a higher incidence of staining in the basement membrane of blood vessel endothelial
cells (Figure 6C). Fibronectin staining within Vhl/ tumors washemorrhagic regions within Vhl/ tumors (Figures 6A and 6B).
In addition, primitive tissues derived from all three germ layers greatly reduced in this cell type (Figure 6D), consistent with
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tion, apoptosis assessed by TUNEL staining (Figures 7G andTable 1. Vhl/ tumors are smaller than controls
7H), did not reveal any quantitative differences between Vhl/
Genotype T/Sa Days Mean Mass (g) and Vhl/ tumors (4.67% and 4.47%, respectively) when nor-
Exp. 1 Vhl/ 6/6 21 3.052  0.670 malized to DAPI-stained nuclei (Figures 7I–7K). Although the
Vhl/.1 5/6 21 1.036  0.257 percentage of TUNEL cells was greater than that of cleaved
Exp. 2 Vhl/ 10/10 21 1.223  0.238
caspase-3 cells, neither apoptosis detection method revealedVhl/.2 10/10 21 0.709  0.092
significant differences between the tumor types. We concludeExp. 3 Vhl/ 5/5 21 1.62  0.371
Vhl/.1 4/4 21 0.53  0.125 that although loss of Vhl is sufficient to dysregulate HIF, this
Vhl/.1HA-VHL 5/5 21 1.76  0.296 alone does not promote teratocarcinoma growth in a subcutane-
Exp. 4 Vhl/ 5/5 28 4.96  1.19 ous tumor model. To the contrary, loss of Vhl seems to impairVhl/.1 3/4 28 0.466  0.318
the growth of primary cells in vivo.
a T/S, number of tumors formed/number of sites injected.
Discussion
Loss of the tumor suppressor VHL is correlated with the devel-
opment of highly vascularized tumors within the kidney, centralpreviously reported data for RCCs and Vhl/ embryos (Ohh et
al., 1998; Hoffman et al., 2001). Histological staining for an nervous system, and retina (Maher and Kaelin, 1997). Insight
into VHL’s role as a tumor suppressor can be found in its abilityendothelial cell-specific antigen (CD34) to demarcate tumor vas-
culature indicated an increase in microvessel density of Vhl/ to bind and target HIF- subunits for ubiquitin-mediated degra-
dation (Maxwell et al., 1999; Cockman et al., 2000; Tanimototumors (47.5 microvessels/mm2 5.0) when compared to Vhl/
tumors (23.1 microvessels/mm2  3.1) (Figures 6E and 6F). et al., 2000). We have shown that whereas loss of Vhl is sufficient
to completely dysregulate HIF, it does not enhance the growthThis statistically significant difference correlated with increased
VEGF secretion by Vhl/ cells in vitro and is consistent with of subcutaneous tumors derived from primary cells. In contrast,
VHL/ RCC cells produce in nude mice rapidly growing xeno-data reported for RCC-derived tumors (Kondo et al., 2002) (p 
0.0256 by Student’s t test) (Figure 6G). When compared to grafts, the growth of which is suppressed by reintroduction of
functional pVHL. The combined effects of pVHL deficiency andcontrols, the phenotype of Vhl/ teratocarcinomas paralleled
that of VHL/ RCCs in terms of fibronectin deposition and additional mutations within the RCC cells may explain this ap-
parent discrepancy.microvessel density. However, pVHL-deficient teratocarcino-
mas are smaller than controls, emphasizing a discontinuity be- The activation of HIF is thought to be an O2-regulated,
multistep pathway requiring  subunit stabilization, nucleartween angiogenesis and tumor proliferation.
translocation, and recruitment of coactivators (Jiang et al., 1997;
Pugh et al., 1997; Kallio et al., 1999; Tanimoto et al., 2000;Vhl/ tumors are deficient in proliferation
but do not exhibit an increase in apoptosis Lando et al., 2002). Recent evidence also suggests that full
activation of HIF is not only dependent upon inhibition of HIF-A possible mechanism for the reduction in tumor volume and
mass could be a decrease in cell growth or an increase in cell prolyl hydroxylation but also asparagyl hydroxylation within the
C-terminal activation domain (CAD) (Lando et al., 2002; Sangdeath. Although undifferentiated Vhl/ cells do not exhibit these
defects in vitro (data not shown), growth in an in vivo tumor et al., 2002). In our studies, normoxic Vhl/ ES cells displayed
constitutive HIF- stability and HIF activity, neither of whichmicroenvironment might reveal such a phenotype. Teratocarci-
noma sections were therefore assessed for expression of cell were substantially induced by hypoxia. The nuclear accumula-
tion of stabilized HIF-1 seen in Vhl/ cells is consistent withcycle markers. Immunostaining for the proliferation marker Ki-
67 (present in the nuclei of all cells not in G0) revealed highly a recent report suggesting that HIF-1 nuclear export is pVHL
dependent (Groulx and Lee 2002). Constitutively stabilizedproliferating regions in Vhl/ tumors, most notably in ectoderm-
derived tissue (Figure 7A). Examination of similar tissue types HIF-1 in Vhl/ cells maintained DNA binding activity and maxi-
mally stimulated the expression of downstream target genes.within Vhl/ tumors also revealed Ki-67 positive staining, but at
lower levels (Figure 7B). Morphometric analysis of these regions Proper HIF regulation was restored by genetic rescue with HA-
VHL. Hence, loss of Vhl leads to the full activation of HIF in ESrevealed that 41.5% of cells within Vhl/ tumors were Ki-67
as compared to 68.1% in Vhl/ tumors and 60.2% in the geneti- cells, even in the absence of additional hypoxic signaling.
Reintroduction of wild-type VHL suppresses the growth ofcally rescued tumors Vhl/ .1HA-VHL (Figure 7C), a statistically
significant difference (p  0.0028 by Student’s t test). This re- pVHL-deficient RCC tumors in nude mice (Gnarra et al., 1996;
Iliopoulos et al., 1996). In contrast, expression of pVHL con-duction in proliferation rate, although modest, may account for
the slower growth rate of Vhl/ tumors over the course of 21 taining  domain mutations that disrupt pVHL/HIF- interaction
does not suppress tumor formation, highlighting the importancedays.
A concomitant increase in the rate of apoptosis could also of HIF regulation for the tumor suppressor function of VHL (Boni-
calzi et al., 2001). pVHL-rescued RCC cells expressing constitu-cause the reduced mass of Vhl/ teratocarcinomas. To assess
this possibility, sections were stained for the apoptotic marker tively stabilized HIF-1 produce smaller tumors than those de-
rived from the parental RCC cell line, indicating that loss ofcleaved caspase-3. Although Vhl/ tumors were significantly
smaller than Vhl/ tumors, there was no corresponding increase VHL contributes to tumor growth through HIF-1-independent
mechanisms (Maranchie et al., 2002). Interestingly, HIF-2 isin apoptosis outside of necrotic regions (Figures 7D and 7E).
Morphometric analysis did not reveal any differences between more frequently upregulated than HIF-1 in renal clear cell carci-
nomas (Turner et al., 2002) and has been implicated as a criticalthe number of cleaved caspase-3 cells in Vhl/ and Vhl/
sections (2.56% and 2.97%, respectively) (Figure 7F). In addi- target for VHL-mediated tumor suppression in renal clear cell
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carcinomas. Our results suggest that constitutive activation of reveal an increase in apoptosis in Vhl/ teratocarcinomas (Fig-
ures 7D–7I). These results suggest that the expression of Bnip-3HIF transcriptional activity in Vhl/ ES cell-derived teratocarci-
nomas promotes tumor angiogenesis, but is itself insufficient in undifferentiated and differentiated ES cells does not induce
apoptosis.to increase tumor growth. This may reflect the fact that our
targeted Vhl/ ES cells differ fundamentally from pVHL-deficient Vhl’s effects on early development and tumor growth are
contrary to those found for other tumor suppressors such asRCC cell lines in at least one important way; specifically, they
have not undergone selection in vivo for the ability to overcome PTEN. Loss of PTEN also results in embryonic lethality, but still
enhances the growth of tumors derived from primary ES cellsproliferation checkpoints and apoptotic controls known to sup-
press tumorigenesis. The chromosomal abnormalities observed and embryonic fibroblasts (Di Cristofano et al., 1998; Stiles et
al., 2002). The aberrant differentiation of Pten/ cells, althoughin RCC cell lines (Gunawan et al., 2001) are consistent with the
idea that genetic instability underlies the multiple genetic hits detrimental to early development, is actually beneficial for tumor
proliferation. In contrast, loss of VHL may only be able to inducethat facilitate tumor formation (Hanahan and Weinberg 2000).
In contrast, the use of Vhl/ ES cells permits assessment of tumor growth in a background of genetic changes. Cytogenetic
abnormalities have been observed in RCC cells, and a minoritypVHL function in an intact genetic background. Taken together,
these results suggest that the tumorigenic phenotype of RCC of RCCs and RCC-derived cell lines have been shown to harbor
p53 mutations (Reiter et al., 1993). Amplifications of the onco-cell lines requires not only pVHL’s HIF-dependent and HIF-
independent functions, but also other oncogenic mutations. genes c-myc and K-ras may also play a role in the generation
of renal clear cell carcinomas (Kozma et al., 1997).The precise role of HIF in tumor development is controversial
due to the conflicting results of several tumor models. While It is important to note that our teratocarcinoma model does
not recreate the selective pressures that generate pVHL-defi-one group found that genetic disruption of the Hif-1 locus
results in the accelerated growth of poorly vascularized Hif- cient human cancers. In many ways, the development of hetero-
geneous tissues within teratocarcinomas reflects the differentia-1/ teratocarcinomas (Carmeliet et al., 1998), others have
shown that the absence of HIF activity in teratocarcinomas and tion of ES cells in early embryogenesis. Loss of Vhl in early
development results in growth retarded embryos, which diefibrosarcomas impairs tumor growth, but not tumor angiogen-
esis (Ryan et al., 1998, 2000; Hopfl et al., 2002). Additional between days E10.5–E12.5 (Gnarra et al., 1997). Vhl/ terato-
carcinomas, although less proliferative, appear to contain moresupport for HIF as a positive regulator of tumor growth has been
obtained from tumor models using nonprimary cells. In three primitive tissue types when compared to controls (data not
shown). The decreased growth and differentiation of Vhl/ tera-different tumor cell lines, loss or disruption of HIF activity also
inhibits expression of HIF target genes, tumor vasculature, and tocarcinomas suggests that pVHL may be required for the prolif-
eration and/or initial differentiation of primary cells. For example,growth (Maxwell et al., 1997; Kung et al., 2000; Hopfl et al.,
2002). Disrupted binding of HIF to coactivators p300 and CBP recent studies from our lab indicate that Vhl/ ES cells generate
reduced numbers of hematopoietic progenitors in in vitro assayscan also attenuate tumor growth (Kung et al., 2000). Therefore,
the full oncogenic consequences of HIF dysregulation are still (F.A.M. and M.C.S., unpublished data). In conclusion, our data
suggest that although inactivation of VHL’s tumor suppressorunresolved and will probably depend considerably on genetic
background. functions can contribute to the malignancy of renal cancer,
disruption of these same pathways in pluripotent cells appearsThe meager growth of Vhl/ teratocarcinomas, a rather un-
expected phenotype considering VHL’s role as a tumor suppres- to be detrimental to their growth and/or differentiation.
sor, did not result from increased apoptosis in Vhl/ ES cell-
Experimental proceduresderived tumors. This point was of particular interest, as the
proapoptotic gene Bnip-3 has recently been described as a
Generation and genotyping of Vhl/ ES cells
novel HIF transcriptional target (Bruick 2000; Sowter et al., 5.0 	 104 Vhl/ ES cells were plated on 10 cm gelatin-coated tissue culture
2001). In fact, Bnip-3 expression has been shown to be stimu- dishes in media containing 4.0 mg/ml of G418 to promote loss of the second
lated in hypoxic regions of human tumors (Sowter et al., 2001). wild-type Vhl allele. Resistant clones were isolated and expanded after 6–7
days of selection. Genomic DNA extracted from cultured ES cells wereAlthough the mRNA transcript of Bnip-3 was highly expressed
digested with HindIII for Southern blot analysis using a probe generatedin both normoxic and hypoxic Vhl/ cells (Figure 4A), this did not
from an AccI/XbaI fragment from the Vhl 3 UTR. PCR was also used toequate with an increase in cell death or a growth disadvantage in
genotype ES clones. Oligonucleotide primers included those specific forvitro. In fact, doubling time and S phase composition as mea-
wild-type Vhl exon 3, 5-ACT GAA AAC GTC TTC CTC CCT CGG G (reverse)
sured by propidium iodide incorporation of Vhl/ cells did not and wild-type exon 1, 5-GCG GAA GGA CAT ACA GCG ACT GAG CC-3
differ significantly from Vhl/ or Vhl/ cells (data not shown). (forward), and internal neo sequence 5-TGA CTA GGG GAG GAG TAG AAG
GTG GCG-3 (reverse).Furthermore, cleaved caspase-3 and TUNEL staining did not
Figure 5. Decrease in growth of Vhl/ tumors
A: Teratocarcinomas were created by injecting Vhl/, Vhl/.1, and Vhl/.2 ES cells subcutaneously into nude mice. Vhl/ tumors ranged in size but were
considerably smaller than Vhl/-derived tumors.
B: Rate of tumor growth was measured by tumor volume for 21 days.
C: Graph represents the combined results of three separate experiments in which the masses of Vhl/, Vhl/, and Vhl/ .1 HA-VHL tumors after 21 days
of growth were measured. N values are as indicated and bars represent standard error. Vhl/ tumors were significantly smaller than Vhl/-derived tumors.
Genetically rescued Vhl/.1  HA-VHL tumors grew similarly to Vhl/ tumors. Student’s t test revealed a statistically significant difference between tumor
masses, p  0.003.
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Figure 6. Increased hemorrhagic regions and
vasculature of Vhl/ tumors
A and B: Hematoxylin and eosin staining of Vhl/
and Vhl/ tumors.
C and D: Basement membrane expression of fi-
bronectin in Vhl/ endothelial cells (arrows) and
reduced fibronectin deposition in endothelial
cells of Vhl/ tumors (arrows).
E: CD-34 staining of Vhl/ microvessels.
F: Microvessel density in Vhl/ tumors appeared
to be increased as demonstrated by -CD-34
staining.
G: Quantitation of tumor microvessel density. The
microvessel density of Vhl/ tumors was greater
than controls, n  3. Student’s t test revealed
statistically significant differences between tu-
mor types, p 
 0.03. Bars represent standard er-
ror. Final magnifications are 100	 (A and B), 400	
(C and D), and 200	 (E and F).
Generation of rescued ES cell lines HA-tagged VHL cDNA. Clones with evidence of an integration event were
further analyzed by Western blot.Wild-type human cDNA encoding pVHL with an N-terminal hemagglutin
epitope tag (HA-VHL) was obtained as a generous gift from Dr. W. Kaelin.
2 	 107 Vhl/.1 ES cells were electroporated with 20 g of PvuII linearized Western blot analysis
expression construct Station II containing HA-VHL with an SV-40 polyadenyl- For all Western blot and EMSA analyses, 6–7 	 106 cells were plated on 10
ation sequence at the C terminus. Resistant clones were screened by South- cm gelatin coated tissue culture dishes such that the density of the cells at
the time of lysis was 60%–70% confluent. Hypoxia, defined as 1.5% O2,ern blot using a 900 bp probe generated from a HindIII-EcoRI fragment from
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Figure 7. Vhl/ tumors exhibited a decrease in proliferation but no increase in apoptosis
A: Proliferation marker Ki-67 indicated highly proliferating regions of Vhl/ tumors.
B: Expression of Ki-67 in Vhl/ tumors was reduced compared to morphologically similar Vhl/ regions.
C: Quantitation of Ki-67 cells in Vhl/, Vhl/, and Vhl/  HA-VHL tumors. Vhl/ tumors were less proliferative than controls. Student’s t test revealed
statistically significant differences between tumors types, p 
 0.003.
D and E: Expression of apoptotic marker cleaved caspase-3 in non-necrotic regions of Vhl/ tumors. Cleaved caspase-3 staining was not increased in
Vhl/ tumors.
F: Quantitation of cleaved caspase-3 cells in Vhl/ and Vhl/ tumors. No significant differences were observed between genotypes.
G and H: TUNEL staining demarcated apoptotic cells in non-necrotic regions of Vhl/ and Vhl/ tumors.
I: Quantitation of TUNEL cells in Vhl/ and Vhl/ tumors. No significant differences were apparent between genotypes. N values are as indicated and
bars represent standard error. Magnifications 200	 (A–H).
J and K: Corresponding DAPI staining of TUNEL regions in G and H. Magnification 200	.
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was generated using an In Vivo2 hypoxic workstation (Ruskinn Technologies, VEGF was added. Sample values were obtained according to manufacturer’s
protocol. Recorded values were normalized for cell number.Leeds, United Kingdom) for Western and EMSA analyses, or an IG750 vari-
able O2 tissue culture incubator (Jouan Inc.) for reporter and Northern anal-
yses. Glycolytic rate assay
Glycolysis was assayed as the rate of conversion of 3H-Glucose to 3H2O asWhole-cell protein lysates were prepared using WCE buffer: 150 mM
NaCl, 50 mM Tris (pH 7.4), 5 mM EDTA, 0.1% SDS, and Complete Protease previously described (Liang et al., 1997). 1 	 106 cells were washed once
in PBS and media were replaced with 0.5 ml of Krebs buffer and incubatedInhibitor (Roche Molecular Biochemicals). Nuclear and cytoplasmic fractions
of protein extracts were prepared using a modified Dignam protocol (Maltepe for 30 min at 37C. Krebs buffer was then replaced with 0.5 ml of Krebs
buffer containing 10 mM glucose and spiked with 10 Ci of 5-3H-glucose.et al., 2000) with Buffer A further modified to contain 0.1% NP-40 and Buffer
Following incubation for 1 hr at 37C, triplicate 50l aliquots were transferredC containing 300 mM NaCl. For hypoxic extracts, cells were manipulated
to uncapped PCR tubes containing 50 l of 0.2N HCl, and these tubes wereinside a hypoxic chamber using phosphate-buffered saline and Buffer A that
transferred to scintillation vials containing 0.5 ml of H2O such that the waterhad been equilibrated to the hypoxic environment. Extracts were electropho-
in the vial and the contents of the PCR tubes were not allowed to mix. Theresed, transferred, and immunoblotted according to standard protocols us-
vials were sealed and diffusion was allowed to occur for 48 hr. The amountsing 5% nonfat dry milk (Carnation) in Tris-buffered saline/Tween 20 as a
of diffused and undiffused 3H were determined by scintillation counting.blocking agent. Blots were stained with Ponceau S to ensure equal loading.
Appropriate 3H-glucose-only and 3H2O-only controls were included, enablingAntibodies used include: -mouse pVHL (Santa Cruz), - human pVHL (Phar-
the calculation of 3H2O in each sample and thus the rate of glycolysis.mingen), - mouse HIF-1 and HIF-2 (Novus), -mouse Rad-50 (Transduc-
tion Laboratories), and -mouse -tubulin (InnoGenex). Horseradish per-
Lactate secretion assayoxidase-conjugated -rabbit and -mouse secondary antibodies were
Lactate concentrations were indirectly determined by a colorimetric assay,purchased from Cell Signaling Technologies and used at dilutions of 1:2000.
which converts the lactic acid present in the media into H2O2, resulting inECL reagents were purchased from Amersham Biosciences. Blots were
the oxidative condensation of a chromogen precursor (Sigma). Approxi-stripped in 61.5 mM Tris (pH 6.8), 2% SDS, and 100 mM -mercaptoethanol
mately 5	 104 cells were plated on gelatin coated 24-well plates and allowedat 55C for 1 hr before being blocked and re-probed.
to recover overnight. Samples were collected and individual cell counts were
obtained every 24 hr for 2 days thereafter.Electrophoretic mobility shift assay (EMSA)
EMSA analyses have been previously described (Maltepe et al., 2000). In
Mouse teratocarcinoma assaybrief, 5 g of nuclear extracts were incubated in binding buffer consisting
5	 106 cells were suspended in 100 l of phosphate-buffered saline (Gibco)of 10 mM Tris-HCl (pH 7.5), 50 mM NaCl, 50 mM KCl, 1 mM MgCl2, 5 mM
and injected subcutaneously into the dorsal area of 4- to 6-week-old femaledithiothreitol, 1 mM EDTA, and 5% glycerol to which 0.05 mg/ml bovine
NIH-III immunodeficient mice (Taconic). After 7 days, tumors were measuredserum albumin, 0.025 g/ml of CREB oligo, 106 dpm of labeled probe, and,
every 2–3 days with calipers in the two greatest dimensions to calculatewhere indicated, 0.5 l of polyclonal -ARNT antiserum (Novus) were added.
tumor volume. After 21 or 28 days, tumors were excised, photographed,The 24 bp oligonucleotide probe was derived from the erythropoietin HRE,
weighed, frozen for protein assays, and fixed in 4% paraformaldehyde.
5-GCC CTA CGT GCT GTC CTC A-3.
Immunohistochemistry
Reporter assays Tumor samples were fixed in 4% paraformaldehyde and paraffin embedded
The HRE-luciferase reporter constructs were previously described (Arsham by standard techniques. Six micrometer sections of each sample were incu-
et al., 2002). Transfection efficiency was assessed by cotransfection of a bated overnight with antibodies generated against fibronectin (BD Scientific),
renilla luciferase gene under the control of a minimal tyrosine kinase pro- cleaved caspase-3 (Calbiochem), Ki-67 (Novacastra), and CD-34 (BD Scien-
moter. Where indicated, cells were also cotransfected with plasmid encoding tific). A TUNEL assay In Situ Cell Death Detection Kit was utilized according
HA-tagged full-length human pVHL. For transient tansfections, 2 	 106 ES to the manufacturer’s protocol (Roche). -mouse and -rat secondary anti-
cells were plated on gelatin-treated 6-well plates and allowed to recover bodies were biotinylated and staining achieved by a strepavidin-biotin sys-
overnight. Cells were transfected the next morning using Lipofectamine tem conjugated with horseradish peroxidase (Vector Lab). Fibronectin, CD-
Plus reagent (Gibco BRL) according to manufacturer’s protocol. Cells were 34, and cleaved caspase-3 photographs were taken with a Nikon N6006 35
transfected for 4 hr and one half of each sample was exposed to hypoxia mm camera. Ki-67 photographs were taken with a Spot RT slider digital
for 18 hr. Proteins were extracted from samples using reporter lysis buffer camera (Diagnostic Instruments Inc.) with a magnification of 0.76	. Morpho-
and dual luciferase assays were performed according to manufacturer’s metric analysis was performed on three to five randomly chosen sections
guidelines (Promega). of each tumor using the analytical program Image Pro (Phase 3 Imaging).
The number of positive cells was calculated as the total area of positive
Northern analysis staining divided by the area of an individual positive cell. The percentage
For Northern blots, 2–3 	 106 cells/10 cm tissue culture dish were plated positive cells were calculated as the number of positive cells divided by the
and allowed to recover overnight. Where indicated, cells were incubated in total number of cells.
hypoxia for 18 hr. All cells were lysed in Trizol (Invitrogen) according to
manufacturer’s instructions in ambient air. Twenty micrograms of total RNA Acknowledgments
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